Drugs / fosbretabulin
fosbretabulin
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03014297 | Mar 2017 → Jun 2018 | neuroendocrine neoplasm | Lowell Anthony, MD | Terminated | No outcome recorded |
| Phase 1 | NCT01052363 | Jan 2010 → ? | central nervous system neoplasm | West Virginia University | Withdrawn | No outcome recorded |
| Phase 1 | NCT00395434 | Sep 2006 → Jan 2007 | neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00003768 | Sep 1998 → Jul 2001 | cancer of unknown primary site | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003698 | Jul 1998 → Dec 2003 | cancer of unknown primary site | University of Glasgow | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02055690 | Sep 2014 → Nov 2017 | ovarian cancer | The Christie NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 1/2 | NCT00077103 | Nov 2003 → Feb 2007 | head and neck cancer | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01570790 | May 2003 → Jun 2005 | age-related macular degeneration, choroidal neovascularization | Johns Hopkins University | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT02279602 | Dec 2014 → Aug 2016 | neuroendocrine neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02132468 | Sep 2014 → Jun 2016 | neuroendocrine neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01305213 | Mar 2011 → Aug 2016 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01023295 | Jul 2009 → Aug 2010 | perifoveal exudative vascular anomalous complex | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00653939 | Mar 2008 → Jul 2011 | neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01423149 | Mar 2005 → Jan 2007 | choroidal neovascularization, degenerative myopia | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00113438 | Mar 2005 → Feb 2007 | cancer | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00060242 | Feb 2003 → Feb 2007 | head and neck cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00507429 | Aug 2007 → Oct 2011 | thyroid gland undifferentiated (anaplastic) carcinoma | Mateon Therapeutics | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02641639 Comparator | Jun 2016 → Oct 2017 | refractory malignant neoplasm | Mateon Therapeutics | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01701349 Comparator | Mar 2015 → Apr 2017 | thyroid gland undifferentiated (anaplastic) carcinoma | Mateon Therapeutics | Withdrawn | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fosbretabulin | “OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas” NCT01052363 ↗13“continue once every three weeks fosbretabulin infusions” NCT02279602 ↗ |
| Known as | CA-4DP | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | CA4P | “The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients...” NCT01570790 ↗ |
| Known as | Combretastatin A4 Phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00395434 ↗ |
| Known as | Fosbretabulin Combretastatin A4-Phosphate, CA4P | “Fosbretabulin Combretastatin A4-Phosphate, CA4P” NCT02641639 ↗ |
| Known as | FOSBRETABULIN DISODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Fosbretabulin disodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Fosbretabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Fosbretabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Phosbretabulin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Zybrestat | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Modality | Small molecule | — CHEMBL1206232 ↗ |
| Route | Intravenous | “weekly intravenous infusion” NCT00003698 ↗ |